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B Fig. 11 A and B. Western
blot and quantification of
PAD2 protein in human
ALS spinal cord,




human ALS spinal cord,
respectively P values are
from comparing ALS
patients and non-ALS
controls. ** = p<0.01.
Fig. 4 A and B. Double
immunofluorescence staining
of spinal cord sections for
GFAP and citrullinated
proteins from different
disease stages in SOD1G93A
and PFN1C71G, respectively.
Fig. 5 A and B. Western blots of PAD2 protein expression in cervical spinal cord (CSC), brainstem (BS)
cerebellum (CB) and cortex (CTX) in SOD1G93A and PFN1C71G mouse models respectively. C and D.
Quantification of PAD2 protein band intensity in (A) and (B), respectively. E and F. Western blot and
quantification of citrullinated proteins in SOD1G93A and; G and H. in PFN1C71G mouse model.
Fig. 3 A and B. Western blot and
quantification of citrullinated proteins
using the anti-modified citrulline
(AMC) antibody detection method in
SOD1G93A mouse model; and C-D in
PFN1C71G mouse model. P values are
from student t-test comparing
transgenic mice with their age matched
controls. **= p<0.01, **** = p<0.0001.
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Abstract
PAD2 is increase in SOD1G93A and PFN1C71G ALS 
mouse models
PAD2 is progressively increased in astrocytes and 
decreased in neurons in SOD1G93A and PFN1C71G
ALS mouse models
Amyotrophic lateral sclerosis (ALS) is a deadly neurodegenerative disease characterized
by loss of motor neurons, paralysis and eventual death. The mechanism of ALS is still
incompletely understood, and the disease is to date without an effective remedy. Protein
arginine deiminase 2 (PAD2) converts peptidyl-Arginine into peptidyl-Citrulline, a post-
translational modification referred to as citrullination. Aberrant expression of PAD2 and
protein citrullination are increased in several neurodegenerative conditions. Whether this
increase is involved in ALS is unknown. In this study, we investigated PAD2 and protein
citrullination in two genetic mouse models of ALS expressing human mutant SOD1G93A
and PFN1C71G, and in human ALS spinal cord. We show that PAD2 gene expressions and
protein citrullination are increased along ALS progression. These changes occur in areas
with the most severe motor neuron degeneration including the spinal cord, and brainstem.
We show that the increase in PAD2 and citrullinated proteins occur specifically in
astrocytes, while decreasing in neurons. Citrullinated proteins also form non-astrocyte
aggregate patterns; and are dominantly expressed in insoluble protein fractions.
Furthermore, the ALS mice spinal cord shows altered citrullinome. Finally, knocking out
PAD2 prevented protein citrullination in SOD1G93A mice, quicken disease onset, while
slowing disease progression. These results demonstrate that aberration of PAD2 protein
citrullination are key characteristics of reactive astrogliosis, and possibly drive some type
of protein aggregation in the pathogenesis of ALS. Because protein citrullination alters
protein functions, our results suggest that PAD2 and protein citrullination play a role in
astrogliosis and astrocytic toxicity in ALS and other neurodegenerative conditions.
Protein citrullination is increased in SOD1G93A
and PFN1C71G ALS mouse models
Protein citrullination increase in astrocytes in 
SOD1G93A and PFN1C71G ALS mouse models
The increase in PAD2 and protein citrullination 
correlates spatially with neurodegeneration in 
ALS mouse models
Citrullinated proteins increase in insoluble 
fractions in SOD1G93A and PFN1C71G ALS mouse 
models
PAD2 and Protein citrullination increase in 
Human ALS spinal cord
Citrullinated proteins forms non-astrocyte 
aggregate patterns in SOD1G93A and PFN1C71G
ALS mouse models
Our results show that PAD2 expression and protein citrullination increase as the
disease progresses in two different genetic mouse models of ALS expressing
mutant SOD1 and PFN1; and in ALS patients. This increase particularly occurs in
the astrocytes, while decreasing in neurons. The alteration of PAD2 and protein
citrullination seen in these mouse models coincides with areas showing motor
neuron degeneration in ALS. The ALS mice spinal cord citrullinome shows a
significant alteration in a wide range of protein classes and functional pathways.
In addition, citrullinated proteins form non-astrocyte aggregate patterns; and are
dominantly expressed in insoluble protein fractions, suggesting citrullination may
possibly drive protein insolubility. Finally, PAD2 knockout prevented protein
citrullination in ALS mice, quickens disease onset, while slowing disease
progression. These results suggest that dysregulation of PAD2 and protein
citrullination contribute in the pathogenesis of ALS.
Fig. 1. A and B. Quantitative real-
time PCR of PAD2 mRNA from
the lumbar spinal cords of mice
expressing mutant SOD1G93A and
mutant PFN1C71G, respectively. C
and D. Western blot and
Quantification of PAD2 protein
from the lumbar spinal cords of
mice expressing mutant SOD1G93A
and mutant PFN1C71G,
respectively. P values are from
student t-test comparing transgenic
mice with their age matched




staining of PAD2 in
ventral horn lumbar
spinal cords of mutant
SOD1G93A and
PFN1C71G mouse
models. B and C.
Double
immunofluorescence
staining for PAD2 and
GFAP in ventral horn






intensity in (B and C).
F and G. Double
immunofluorescence
staining for PAD2 and





and I. Quantification of
PAD2 fluorescent
intensity in NeuN
positive neurons in (F
and G).
PANTHER classification of citrullinated 
proteins in SOD1G93A ALS mouse model
Proteomics demonstrate alteration of protein 
citrullination in SOD1G93A ALS mouse model
A
Fig. 8 Double immunofluorescence staining in the white matter of nTg and both ALS mouse models at paralysis
stage for A. GFAP and citrullinated proteins. Arrow shows non-astrocyte aggregate patterns of citrullinated
proteins B. C46F and citrullinated proteins. Arrowhead shows colocalization of SOD1 aggregate with
citrullinated proteins. C. pPFN1 and citrullinated proteins. Arrowhead shows colocalization of pPFN1 with
citrullinated proteins. NB. Lower panels are magnified images of middle panels
B C
Fig. 9 A and B. Blots from
sedimentation assay showing
citrullinated proteins dominantly
expressed in insoluble protein
fraction from SOD1G93A and
PFN1C71G mouse models,
respectively, at different disease
stages.
PAD2 knockout prevents protein citrullination 
in SOD1G93A mouse model.
Fig. 7. A. Protein classification of significantly altered citrullinated 
proteins by Panther Classification System. B. Table 3.  Number of ALS-
altered citrullinated proteins represented in various Panther Functional 
Pathways
Fig. 6 A. Schematic 
representation for identifying 
citrullinated proteins. B. Table 1. 
Mouse spinal cord citrullinome  
and its changes in SOD1G93A
mice. G93A(p) = paralysis stage; 
nTg(o) = onset stage; nTg(p) = 
age-matched controls for 
G93A(P); nTg(o) = age-matched 
controls for G93A(o); 
C. Volcano plot of the significantly altered citrullinated 
proteins. D. Table 2. mRNA expression in the citrullinated 
proteins that are altered in SOD1G93A mice. This summary is 
based on data published by Maniatis et. Al., 2019.
Fig. 10 A. PAD2 Knockout
does not affect protein
expression of PADs 3 and 4.
in SOD1G93A ALS Mice. B.
PAD2 Knockout prevents
protein citrullination in
SOD1G93A ALS Mice. C.
PAD2 knockout accelerated
disease onset but slowed down
the disease progression in
SOD1G93A ALS mice. The
plots are averages of 3-8
animals that have been
monitored throughout their
lifespan. Peak body weight
before the decline are pointed
by arrows.
Summary
